Life Sciences

Innovation, patient access and pricing are driving the transformation of the life sciences.

This is a time of enormous disruption in the life sciences sector. New IP being generated and new entrants from the technology industry are accelerating the dawn of personalised medicine.

With a nearly constant stream of capital and emerging technologies, biotech startups have proliferated; investors and Big Pharma are chasing innovations, and drug approvals have hit record levels globally.

Talent acquisition has become a key indicator of future success, with well-funded early stage companies and global pharma companies competing on an increasingly level playing field.

Singapore

The centre of gravity for the life sciences market is set to shift east. The world’s largest pharmaceutical companies are bolstering their operations in the region, whilst Asian companies seek to strengthen their offering and expand west.

But there remain challenges. corruption, pricing, and IP are all key concerns. Whilst the difficulty in understanding the foundations of doing business in different Asian countries only compounds these risks.

Odgers Berndtson’s global Life Sciences Practice works with MNCs and domestic Asian companies to mitigate many of these risks. By securing leaders with regional experience at board and executive level, our clients secure the experience they need to succeed in Asia.